These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28159504)

  • 41. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
    Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
    J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Student pharmacist perceptions of participation in hands-on naloxone counseling.
    Hines J; Deja E; Black EP
    Curr Pharm Teach Learn; 2018 Jun; 10(6):712-716. PubMed ID: 30025770
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A naloxone and harm reduction educational program across four years of a doctor of pharmacy program.
    Maguire MA; Pavlakos RN; Mehta BH; Schmuhl KK; Beatty SJ
    Curr Pharm Teach Learn; 2018; 10(1):72-77. PubMed ID: 29248078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. First Responder knowledge, perception and confidence in administering naloxone: Impact of a pharmacist-provided educational program in rural Mississippi.
    Crocker A; Bloodworth L; Ballou J; Liles AM; Fleming L
    J Am Pharm Assoc (2003); 2019; 59(4S):S117-S121.e2. PubMed ID: 31109810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Naloxone Administration for Opioid Overdose Reversal in the Prehospital Setting: Implications for Pharmacists.
    Weaver L; Palombi L; Bastianelli KMS
    J Pharm Pract; 2018 Feb; 31(1):91-98. PubMed ID: 28399697
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In-flight opioid overdose and the availability of onboard naloxone: An international survey of commercial airlines.
    Wang JJ; Poirier V; Carvalho AM; Biary R; Su MK
    Travel Med Infect Dis; 2019; 30():123-124. PubMed ID: 31216490
    [No Abstract]   [Full Text] [Related]  

  • 47. Survey of Southern Wisconsin Needle Exchange Clients Regarding Opioid Overdose and Naloxone Use.
    Baltes A; Devo B; Kaiser M; Birstler J; Brown RT
    WMJ; 2019 Jul; 118(2):84-87. PubMed ID: 31532934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Armed with naloxone.
    Goodloe JM; Dailey MW; Heightman AJ
    JEMS; 2014 Aug; 39(8):28-33. PubMed ID: 25204112
    [No Abstract]   [Full Text] [Related]  

  • 49. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.
    Green TC; Case P; Fiske H; Baird J; Cabral S; Burstein D; Schwartz V; Potter N; Walley AY; Bratberg J
    J Am Pharm Assoc (2003); 2017; 57(2S):S19-S27.e4. PubMed ID: 28214219
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subcutaneous naloxone: a less rude awakening?
    Horowitz Z
    Acad Emerg Med; 1998 Apr; 5(4):283-5. PubMed ID: 9562188
    [No Abstract]   [Full Text] [Related]  

  • 51. Intranasal naloxone for life threatening opioid toxicity.
    Kelly AM; Koutsogiannis Z
    Emerg Med J; 2002 Jul; 19(4):375. PubMed ID: 12101174
    [No Abstract]   [Full Text] [Related]  

  • 52. OPIOID CRISIS. Prehospital naloxone administration for opioid-related emergencies.
    Drennan IR; Orkin AM
    JEMS; 2016 Mar; 41(3):36-9. PubMed ID: 27120853
    [No Abstract]   [Full Text] [Related]  

  • 53. The naloxone option.
    Prabhu A; Abaid B; Khaleel MS; Naik S; Lippman M; Lippman S
    J Fam Pract; 2018 May; 67(5):288;290;292. PubMed ID: 29726853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Should we use naloxone epidurally?
    Blaise G
    Can J Anaesth; 2003 Nov; 50(9):875-8. PubMed ID: 14617581
    [No Abstract]   [Full Text] [Related]  

  • 55. Naloxone nasal spray.
    Drug Ther Bull; 2019 Sep; 57(9):137-140. PubMed ID: 31296655
    [No Abstract]   [Full Text] [Related]  

  • 56. Expanding access to naloxone in the United States.
    Doyon S; Aks SE; Schaeffer S; ; ;
    Clin Toxicol (Phila); 2014 Dec; 52(10):989-92. PubMed ID: 25283253
    [No Abstract]   [Full Text] [Related]  

  • 57. Pilot implementation of the PharmNet naloxone program in an independent pharmacy.
    Eldridge LA; Meyerson BE; Agley J
    J Am Pharm Assoc (2003); 2023; 63(1):374-382.e12. PubMed ID: 36209035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is subcutaneous or intramuscular naloxone as effective as intravenous naloxone in the treatment of life-threatening heroin overdose?
    Wasiak J; Clavisi O
    Med J Aust; 2002 May; 176(10):495. PubMed ID: 12065016
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
    Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
    J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An increase in per-patient naloxone requirements in an opioid epidemic.
    Birmingham LE; Nielson JA
    Am J Emerg Med; 2017 Dec; 35(12):1958-1959. PubMed ID: 28633907
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.